BeiGene Trial of Lung-Cancer Treatment Reaches Primary Endpoints
By Ben Glickman BeiGene's trial of the use of tislelizumab to treat resectable non-small cell lung cancer, when combined with chemotherapy, reached its dual...
Stay updated with breaking news from Bgne. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
By Ben Glickman BeiGene's trial of the use of tislelizumab to treat resectable non-small cell lung cancer, when combined with chemotherapy, reached its dual...
By Denny Jacob BeiGene's brukinsa received a positive opinion recommending its approval from an European Medicines Agency committee. The biotechnology...
BeiGene, Ltd. (NASDAQ:BGNE – Get Free Report) has been assigned an average rating of “Moderate Buy” from the twelve research firms that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. The average 1-year target price among […]
BeiGene, Ltd. (NASDAQ:BGNE – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the twelve analysts that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 12 month target price among brokerages […]
BeiGene (NASDAQ:BGNE – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Monday. BGNE has been the subject of several other reports. 22nd Century Group reaffirmed a “downgrade” rating on shares of BeiGene in a research note on Friday, […]